Postpartum depression affects about one in seven women after childbirth, causing persistent sadness, anxiety, and difficulty bonding with the baby. Standard treatment combines therapy with antidepressants like sertraline or escitalopram, which take weeks to work. Research now focuses on faster-acting treatments and on understanding the hormonal changes that trigger depression in some women.
What's actually going on in research
Trials are testing zuranolone, a pill designed specifically for postpartum depression that works in days rather than weeks. Researchers are also studying brexanolone infusions for severe cases, psilocybin-assisted therapy, digital mental health tools, and the role of allopregnanolone — a hormone that drops sharply after delivery. Some studies examine whether treating depression during pregnancy prevents postpartum symptoms.
Rapid-acting neurosteroids
Zuranolone was FDA-approved in 2023 for postpartum depression and works within two weeks by restoring GABA activity in the brain. Trials continue to refine dosing and identify who benefits most from this approach.
Prevention trials
Studies are testing whether starting antidepressants in late pregnancy can prevent postpartum depression in high-risk women. Other trials examine whether psychological interventions during pregnancy reduce the likelihood of depression after birth.
Digital interventions
Researchers are testing apps and online therapy programs designed for new mothers, aiming to improve access to treatment. Some studies examine whether these tools work as well as in-person care.
What to know before you search
Eligibility typically depends on symptom severity, timing since delivery, whether you're breastfeeding, and previous mental health history.
What types of trials are currently open
- Treatment trials — Testing medications like zuranolone or new antidepressants to see how quickly they relieve postpartum depression symptoms.
- Prevention trials — Studying whether medications or therapy started during pregnancy can prevent depression after delivery in women at high risk.
- Infusion studies — Testing brexanolone, a neurosteroid given as a continuous infusion over 60 hours for severe postpartum depression.
- Therapy trials — Comparing different types of counseling, including cognitive behavioral therapy and interpersonal therapy, often delivered through telehealth.
- Digital health studies — Testing smartphone apps and online programs that provide therapy, symptom tracking, and support for new mothers.
Recently added Postpartum Depression trials
Smartphone-Assisted Single-Session Psychotherapy Intervention for Postpartum Depression
Our goal is to learn whether a single session of online psychotherapy, followed by four weeks of support from a smartphone app (Motherly), reduces depressive symptoms in women with postpartum depression. Specifically, we want to see if mothers receiving this care show greater improvement-as evaluated by a healthcare professional-than those waiting to start treatment. We will compare the intervention with a waitlist control. Women in the waitlist group receive the same intervention after 4 weeks. Participants will: * Attend one online psychotherapy session of about 90 minutes, based mainly on behavioral activation; * Use the Motherly app on their own for 4 weeks to implement behavioral strategies learned during the therapy session and access psychoeducational content; * Complete remote clinical interviews and questionnaires at weeks 1, 2, 4 and 8 The study also explores which participant characteristics predict benefit (moderators), whether changes in behavioral activation and access to rewarding activities explain the effect (mediators), and how therapeutic alliance and app engagement relate to outcomes.
Restoring Emotional Needs With Exogenous Ketones for Women With Postpartum Depression
The purpose of this study is to evaluate the feasibility, acceptability, and preliminary efficacy of a 16-week, fully remote, multimodal intervention combining exogenous ketone supplementation (Qitone™) with group-mediated cognitive behavioral (GMCB) counseling with structured exercise for women diagnosed with postpartum depression (PPD). The study aims to determine whether integrating biochemical, behavioral, and physical activity strategies can improve depressive symptoms, metabolic health, and psychosocial functioning during the postpartum period.
Find Postpartum Depression trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.